Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
pharmaceuticals: Archive
Top Research Reports for Microsoft, Eli Lilly & Costco
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Eli Lilly and Company (LLY) and Costco Wholesale Corporation (COST), as well a micro-cap stock Koss Corporation (KOSS).
MSFTNegative Net Change LLYNegative Net Change UPSNegative Net Change ORLYPositive Net Change COSTPositive Net Change KOSSPositive Net Change BKNGNegative Net Change
computers pharmaceuticals retail tech-stocks
Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week
by Zacks Equity Research
Incyte (INCY) rises 7% in a week as investors appreciated the company's buyback plan to boost returns.
INCYPositive Net Change LGNDPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control
by Zacks Equity Research
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
LLYNegative Net Change LGNDPositive Net Change ANIPNegative Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
by Zacks Equity Research
Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.
JNJPositive Net Change LGNDPositive Net Change ANIPNegative Net Change ENTXNegative Net Change
pharmaceuticals
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
by Kinjel Shah
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
JNJPositive Net Change NVONegative Net Change MRKPositive Net Change LLYNegative Net Change BAYRYPositive Net Change
pharmaceuticals
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
by Zacks Equity Research
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
BIIBPositive Net Change LGNDPositive Net Change HRTXNegative Net Change IONSNegative Net Change
biotechs medical pharmaceuticals
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
by Sundeep Ganoria
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
RHHBYPositive Net Change AMGNNegative Net Change ALTNegative Net Change VKTXNegative Net Change NVONegative Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
3 Stocks to Buy Following Positive Earnings Results
by Derek Lewis
All three of these companies saw buyers step up post-earnings, reflecting the positivity of their results.
AAPLPositive Net Change LLYNegative Net Change CROXNegative Net Change
apparel pharmaceuticals retail tech-stocks
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
LGNDPositive Net Change ANIPNegative Net Change KODNegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
by Ekta Bagri
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
SNYNegative Net Change BMYNegative Net Change MRNAPositive Net Change NVAXNegative Net Change FULCNegative Net Change
biotechnology medical pharmaceuticals
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
by Kinjel Shah
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.
NVONegative Net Change MRKPositive Net Change LLYNegative Net Change
pharmaceuticals
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
by Zacks Equity Research
Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
RHHBYPositive Net Change NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs medical pharmaceuticals
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
by Zacks Equity Research
Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.
BMYNegative Net Change LGNDPositive Net Change ANIPNegative Net Change TSVTNegative Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Broadcom, Merck, Airbnb, ONEOK and PG&E
by Zacks Equity Research
Broadcom, Merck, Airbnb, ONEOK and PG&E are included in this Analyst Blog.
PCGPositive Net Change MRKPositive Net Change OKEPositive Net Change AVGONegative Net Change ABNBNegative Net Change
pharmaceuticals
Top Stock Reports for Broadcom, Merck & Airbnb
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co., Inc. (MRK) and Airbnb, Inc. (ABNB).
PCGPositive Net Change MRKPositive Net Change OKEPositive Net Change ENBNegative Net Change AVGONegative Net Change ABNBNegative Net Change
internet-content pharmaceuticals semiconductor
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
by Zacks Equity Research
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
by Zacks Equity Research
Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
pharmaceuticals
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
by Zacks Equity Research
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
UTHRPositive Net Change LGNDPositive Net Change ANIPNegative Net Change ALLONegative Net Change
biotechs cell-therapy earnings medical pharmaceuticals
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
by Zacks Equity Research
AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.
ABBVPositive Net Change CERENegative Net Change THRDNegative Net Change
pharmaceuticals
Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
by Zacks Equity Research
Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
NVONegative Net Change LGNDPositive Net Change ANIPNegative Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
by Zacks Equity Research
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
MRKPositive Net Change MRNAPositive Net Change LGNDPositive Net Change ANIPNegative Net Change
pharmaceuticals
Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales
by Zacks Equity Research
Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.
REGNPositive Net Change JNJPositive Net Change BAYRYPositive Net Change LGNDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
AZNNegative Net Change BMYNegative Net Change MRKPositive Net Change LGNDPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
by Zacks Equity Research
Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
REGNPositive Net Change SNYNegative Net Change LGNDPositive Net Change ANIPNegative Net Change
pharmaceuticals
Bull of the Day: Veeva Systems (VEEV)
by Benjamin Rains
The tech firm and the stock are proven winners. Now might be the time for investors to heed tried-and-true investment advice and buy Veeva while others are fearful.
VEEVPositive Net Change
biotechnology pharmaceuticals tech-stocks